Introduction
Graft-versus-host disease (GVHD) continues to be a major life-threatening complication after allogeneic stem cell transplantation (SCT), particularly for patients receiving grafts from donors other than HLA identical siblings. Standard post-transplant prophylactic therapy consists of cyclosporine (CsA), in the case of non-T-cell depleted SCT combined with methotrexate or MMF. More recently, instead of CsA, other drugs like tacrolimus or sirolimus (rapamycin) have also been used for the prophylaxis and treatment of GVHD. [1] [2] [3] T cells in the graft are not only important for successful grafting and graft-versus-leukemia (GVL) activity, but also now it is increasingly appreciated that a particular subset of T cells, the CD4 þ CD25 þ regulatory T cells (T REG ), can participate in the control of GVHD. Rapid reconstitution of these cells and functional presence in the graft might downscale the severity of GVHD. Importantly, in several animal models, it was shown that ex vivo expanded and re-infused CD4 þ CD25 þ T REG can selectively suppress GVHD and simultaneously spare the beneficial GVL activity. [4] [5] [6] Recently, it has become clear that signaling by interleukin (IL)-2 is pivotal for regulatory T-cell homeostasis and thymic generation. [7] [8] [9] In the periphery, IL-2 signaling is required for sustaining the T REG population at a size necessary to maintain immune homeostasis. 7, 8 In the thymus, signaling through the common g-chain of cytokine receptors is essential for naturally occurring CD4 þ CD25 þ T REG development. CD4 þ CD25 þ T REG are generated from thymocytes that express the forkhead family transcription factor FoxP3. 10, 11 The induction of FoxP3 designates their fate as T REG . 12 Based on the role of T REG in the prevention of GVHD, and on their dependence on IL-2, there is considerable concern about the impact of blocking IL-2 signaling or IL-2 production by immunosuppressive agents that are used for prophylaxis of GVHD.
CsA inhibits IL-2 transcription by blocking proximal TCR-triggering events, whereas rapamycin is an effective drug by blocking downstream effects on cell-cycle progression in response to growth factors like IL-2. CsA inhibits the activity of calcineurin, which leads to a decreased phosphorylation of the nuclear factor of activated T cells (NFAT). As a consequence, the translocation of this regulatory factor from the cytoplasm to the nucleus is impaired, resulting in a reduced expression of several cytokines, including IL-2. 13 Rapamycin binds to a protein kinase, called the mammalian target of rapamycin, and blocks cell growth and proliferation in response to growth factors like IL-2.
14-16 Here we analyzed the differential effects of CsA and rapamycin on the maintenance and ontogeny of T REG . Here we demonstrate that in contrast to rapamycin, CsA compromises homeostasis in peripheral immune compartments and thymic generation of CD4 þ CD25 þ FoxP3 þ T cells. We propose that the choice of immunosuppression may thus have important implications for the control of GVHD after SCT.
Materials and methods

Mice
C3H (H-2
k ) and BALB/c (H-2 d ) mice were purchased from Charles River Lab (Charles River, Sulzfeld, Germany). Mice were used at 8-12 weeks of age and housed in a specified pathogen-free facility. All experiments were performed according to the guidelines of the Animal Ethics Committee of the Radboud University Nijmegen.
Drug treatment
Cyclosporine A (Novartis, Basel, Switzerland) was delivered subcutaneously by a 14-or 28-day osmotic pump (Alzet, Palo Alto, CA, USA). Rapamycin (Wyeth Europe, Berkshire, UK ) was diluted in vehicle containing sodium carboxymethylcellulose (C-5013 high viscosity; SigmaAldrich, St Louis, MO, USA) and polysorbate 80 (P-8074; Sigma-Aldrich) and administered by intraperitoneal (i.p.) injection on days 0, 1 and 2, and subsequently every other day. PC61 antibody (Bioceros BV, Utrecht, The Netherlands) was administered i.p. in a single dose of 150 mg in 300 ml phosphate-buffered saline.
Cardiac allograft transplantation
Cardiac allografts were placed in an intra-abdominal location using the technique described by Corry et al.
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Graft function was assessed every two days by palpation. The day of rejection was defined as the day of cessation of palpable heartbeat.
Flow cytometry
After the mice were killed, thymus, spleen, lymph nodes and peripheral blood were collected. Cell suspensions of different immune compartments or peripheral blood were depleted of erythrocytes by osmotic shock using a lysis buffer containing 0.15mM NH 4 Cl (Merck, Darmstadt, Germany), 10.0 mM KHCO 3 (Merck) and 0.1 mM Na 2 ED-TA (Sigma-Aldrich, Steinheim, Germany). Subsequently, cells were phenotypically analyzed by three-or four-color fluorescence. Cells were washed twice with phosphatebuffered saline supplemented with 0.2% bovine serum albumin (Sigma). The following antibodies were used: FITC-, PE-, or PE-Cy7-conjugated anti-CD4 (L3T4), FITC-or PE-conjugated anti-CD8 (53-6.7), and biotinconjugated anti-CD25 (7D4) (all from BD Biosciences, Erembodegem, Belgium). All incubations were conducted for 20 min at room temperature and thereafter the cells were washed twice. For secondary staining of biotinconjugated antibodies, streptavidin-PE (BD Biosciences, Erembodegem, Belgium) or Streptavidin-Cy5 (Beckman Coulter, Miami, USA) was used. FoxP3 was determined by intracellular analysis after fixation and permeabilization using a PE-conjugated anti-mouse FoxP3 (FJK-16s) staining set (eBioscience, SanDiego, USA). The samples were run on a Coulter Epics XL, Beckman Coulter (Miami, USA) and at least 100 000-150 000 events were collected based on live lymphocyte gating, as indicated by 5 mg/ml propidium iodide staining. Isotype matched antibodies were used to define marker settings.
Statistics
Statistical analysis was performed using Graphpad Prism 3.0 and Microsoft Excel 2000. For comparisons between groups, we used analysis of variance or Student's t-test where appropriate, assuming unequal variances because of small sample sizes.
Results
CsA results in CD25
þ FoxP3 þ T-cell depletion in peripheral immune compartments The expression of the IL-2 receptor a chain (CD25) converts the intermediate affinity IL-2 receptor (consisting of a b-and g-chain only) to a high-affinity IL-2 receptor, which is required for the normal immune function of T cells 18 and specifically for the maintenance of T REG in the peripheral T-cell pool. 7 Because the expression of CD25 is regulated by IL-2, 19 it can be imagined that blocking IL-2 production or signaling can interfere with CD25 expression and subsequently with T REG physiology. We therefore analyzed the proportion of CD4 þ CD25 þ T cells, with special focus on the CD25 high population, in spleen, lymph nodes and peripheral blood after mice were treated for 7 days with CsA or rapamycin.
First, we determined biologically active drug dosages in vivo, by using our established mouse cardiac allograft model. BALB/c recipients were transplanted with C3H cardiac allografts and monitored for rejection in the absence or presence of treatment with CsA (20 mg/kg/ day) or rapamycin (0.2 mg/kg on alternating days). We confirmed that at these dosages CsA and rapamycin were biologically active as cardiac allograft survival was extended successfully (Figure 1a) . Second, to analyze the effect of single CsA or rapamycin treatment on the established T REG population, we treated Balb/c mice for 7 days with either drug. Overall, we observed that, in the various peripheral immune compartments, the proportion of CD25 high T cells within the CD4 þ subset was significantly reduced upon CsA treatment in a dose-dependent manner, whereas rapamycin-treated and non-treated animals contained similar proportions of these cells (Figure 1b and c). The administration of PBS in osmotic pumps did not decrease the proportion
high T cells. Moreover, 2 weeks after cessation of CsA treatment, the CD4 þ CD25 high T-cell population was restored to normal levels ( Figure 1d ).
IL-2 signaling is also required for the maintenance of FoxP3 expression, which is considered the best marker of T REG and is pivotal for their function. 7 To analyze whether interference in IL-2 signaling by immunosuppressive drugs results in reduction of the number of T REG , and not merely their CD25 expression, intracellular FoxP3 expression was analyzed in combination with CD25 expression. To exclude that a putative effect on T REG was left unnoticed during a relatively short period of treatment (i.e. one week), we treated the mice for 28 days. CsA treatment resulted in a strong reduction of the proportion of CD4 þ FoxP3 þ T cells in the various immune compartments (Figure 2) , which paralleled the observed decrease in CD4 þ CD25 high T cells. CsA T-cell population in the different immune compartments (Figure 3a) . Upon concurrent treatment with PC61 and CsA or rapamycin, we found a sharp reduction of CD4 þ CD25 high T cells in the spleen at day 7 after anti-CD25 injection (Figure 3b) . At 3-4 weeks after anti-CD25 injection, the proportion of CD4 þ CD25 high T cells in the spleen was restored to normal levels, which is indicative of the presence of CD4 þ CD25 high T-cell homeostasis (Figure 3b ). Interestingly, in the presence of CsA, this homeostasis of CD4 þ CD25 high T cells was compromised, whereas treatment with rapamycin allowed a similar recovery of the CD4 þ CD25 high T-cell population as seen in the control animals (Figure 3b and c) 
CsA compromises thymic ontogeny of FoxP3
þ T cells The intracellular processes that are affected by CsA and rapamycin in activated T cells are also involved in maturation and selection of thymocytes. 20 As thymic T REG substantially contribute to the peripheral T REG population, 21 CsA and rapamycin may interfere in the homeostatic control of T REG by affecting T REG genesis in the thymus.
In the thymus, CD4 22 We analyzed the effect of CsA and rapamycin at 7 and 28 days of administration on the different stages of thymic development of CD4 þ T cells. After 7 days of administration, neither CsA nor rapamycin clearly affected the thymic subset composition (Figure 4a) . However, long-term treatment with either CsA or rapamycin resulted in considerable changes in the proportions of the different subsets within the thymus (Figure 4b) . Treatment with CsA led to a reduction of the CD4 þ SP T-cell compartment. In contrast, rapamycin resulted in a reduction of CD4 þ CD8 þ DP thymocytes, with a concomitant relative increase of CD4 À CD8 À DN and CD4 þ CD8 À SP thymocytes. We subsequently evaluated the effect of CsA and rapamycin treatment on the thymic emergence of regulatory T cells. During thymic ontogeny, CD4 þ CD25 þ expression is not the most accurate marker of T REG , since the expression of CD25 can precede the induction of FoxP3, whereas the latter determines the T REG fate. The induction of FoxP3 occurs predominantly in the CD4 þ SP stage or during the transition to this stage from the CD4 þ CD8 þ DP stage. 10 We observed that the proportion of Foxp3 expressing thymocytes within the total CD4 þ compartment was significantly lower in CsA-treated animals as compared to untreated and rapamycin-treated animals (Figure 4c) .
Thus, rapamycin allows for CD4 þ SP thymocyte maturation and induction of FoxP3, whereas CsA compromises CD4 þ SP thymocyte maturation and generation of FoxP3 þ T cells during prolonged treatment.
Discussion
During the last decade, T REG have emerged as an intrinsic part of the immune system, pivotal for the maintenance of tolerance to self-antigens. 23 An important clinical goal is to harness these tolerance-inducing elements, and to facilitate T REG control of the organ destructive potential of selfreactive cells in autoimmune disease and of allo-reactive cells in the transplantation of stem cells or solid organs. Therefore, a more thorough understanding of naturally occurring T REG ontogeny and survival in the presence of currently used immunosuppressive drugs is essential. Here we demonstrate that CsA and rapamycin differentially affect CD4
þ FoxP3 þ T REG homeostasis in vivo. After short-term treatment, CsA reduced the peripheral T REG population, but did not alter thymic subset composition. In agreement with our data, it has been shown that TCR triggering and IL-2 are both essential for the maintenance of the T REG population in the periphery, 7, 24 whereas IL-2 was found to be dispensable for the development of T REG in the thymus. [7] [8] [9] Setoguchi et al. demonstrated that neutralization of IL-2 in vivo results in a decrease of T REG numbers with similar kinetics as we observed during treatment with CsA. In that study it was concluded that peripheral T REG depend on IL-2 produced by CD25 low T cells. 9 It thus appears that the interference of CsA with TCR signaling and IL-2 production affects T REG homeostasis at least in part by impairing the maintenance of the T REG population in the periphery.
After depletion of T REG , we observed a compromised recovery of the regulatory T-cell population in the presence of CsA. In addition, we found a reduced generation of CD4 þ FoxP3 þ SP cells in the thymus after prolonged treatment with CsA. This is in agreement with earlier observations that CsA inhibits the development of CD4 þ SP thymocytes from their CD4 þ CD8 þ DP precursors. 25 The commitment to the CD4 þ T-cell lineage is controlled by TCR-signals of sufficient strength or duration. 22, 26 There is also a direct link between TCR triggering and FoxP3 induction, 27 which occurs predominantly in the CD4 þ SP thymocyte stage or during the transition from CD4 þ CD8 þ DP cells to this stage. 11, 28 CsA can inhibit this thymic generation of CD4 þ FoxP3 þ T REG by impairment of TCR signaling, and more specifically by reducing the NFATdependent FoxP3 promotor activity. 29 Rapamycin inhibits biochemical pathways required for the cell cycle progression from the G1 to S phase, but allows the initial signal transduction upon TCR triggering. 15 We found that rapamycin does not affect the thymic CD4 þ FoxP3 þ T-cell generation. This is supported by a previous study in which it was demonstrated that rapamycin inhibits the proliferation of CD4 þ CD8 þ DP thymocytes, but in contrast to CsA, allows the maturation of CD4 þ SP thymocytes. 30 Of interest, the T REG that mediate the down regulation of GVHD were demonstrated to be recent thymic emigrants, as revealed by the assessment of T-cell recombination exclusion circles. 31 Regarding the essential role for IL-2 in the peripheral survival of CD4 þ CD25 þ T cells, it is interesting that these cells differ from primed CD4 þ T cells in their IL-2 receptor signaling pathway. In CD4 þ CD25 þ T cells, the effects of IL-2 are mediated by activation of the Janus kinase/STAT pathway, whereas rapamycin-sensitive downstream targets of phosphatidyl-inositol 3-kinase (like p70 s6kinase ) are not activated. 32 It is thus conceivable that rapamycin does not affect the IL-2-dependent peripheral survival of T cells, whereas CsA treatment compromises the homeostasis of this T REG population. So far, the finding that CsA can contribute to chronic GVHD in experimental models was ascribed to the disruption of clonal deletion mechanisms in the thymus, resulting in the export of auto-reactive T cells. 33, 34 Rapamycin was supposed to contribute to tolerance induction by allowing activation induced cell death of effector cells. [35] [36] [37] We think that the contrasting effects of CsA and rapamycin on the generation and homeostasis of CD4 þ FoxP3 þ T REG that we describe here may offer additional explanations for the dissimilar influence of these drugs on tolerance induction in various models. In agreement with our findings, CsA treatment of newborn mice was found to cause autoimmune diseases similar to those observed following neonatal thymectomy, which also has a detrimental effect on T REG homeostasis. 38 Moreover, our data fit with the observations that CsA decreases the expansion of adoptively transferred FoxP3 þ T cells, 39, 40 whereas rapamycin treatment spares T REG in vivo. 39, 41 Decreased FoxP3 levels have been associated with GVHD in several studies. 31, [42] [43] [44] Expression of Foxp3 negatively correlated with the severity of GVHD in patients, but positively correlated with recent thymic emigrants. These findings substantiate that defective thymic function contributes to the impaired reconstitution of immune regulatory mechanisms following transplantation. 31, 43 Here we extend these findings by demonstrating that CsA has a detrimental effect on thymic generation of CD4 þ FoxP3 þ T REG ,
CsA compromises the FoxP3 þ T-cell population JJA Coenen et al whereas rapamycin is permissive for the thymic generation of T REG .
In conclusion, CsA and rapamycin differentially affect the generation and homeostasis of CD4 þ FoxP3 þ T REG in vivo. As peripheral tolerance induction is a prerequisite for successful treatment outcome after SCT, this may challenge the use of CsA as standard drug of choice.
